Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Contact Us

Send us a Message


MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

STAY INFORMED!

Brain MRI surveillance without prophylactic cranial irradiation reduces cognitive failure risk in patients with SCLC

15

Sep 2026

Brain MRI surveillance without prophylactic cranial irradiation reduces cognitive failure risk in patients with SCLC

In the SWOG S1827 MAVERICK phase III randomized trial, patients with small-cell lung cancer (SCLC) who underwent regular brain MRI surveillance without prophylactic cranial irradiation (PCI) had significantly better cognitive failure–free survival (the primary endpoint of the trial), without an apparent difference in overall survival, according to results presented at the Presidential Symposium of the IASLC 2026 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer, in Seoul, Republic of Korea.

READ MORE
A study of more than 21,000 adults found an unusual link between psilocybin and diet

15

Sep 2026

A study of more than 21,000 adults found an unusual link between psilocybin and diet

Using data from more than 21,800 adults in two UK birth cohorts, researchers found that lifetime psilocybin and LSD use was associated with stronger pro-environmental attitudes and a greater likelihood of following a vegetarian diet, with psilocybin showing the clearer dietary pattern. Mediation analyses suggested that environmental attitudes statistically accounted for the psilocybin-vegetarianism association and part of the association with lower red meat consumption, but the observational design cannot establish causation.

READ MORE

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.